AGN-190584

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

28 competitors in Presbyopia

#DrugCompanyPhaseTrials

1

Bromday

BBausch Health Americas, Inc.

Approved

—2

Alphagan

AbbVie

Phase 3

13

Alphagan

Novartis

Phase 3

14

Isopto Carpine

AAdvanz Pharma

Phase 3

25

Pilocarpine Hcl

AbbVie

Phase 3

46

Miostat

FFalcon

Phase 2

37

Restasis

TTaiwan Bio Therapeutics Inc.

Phase 1

—8

AGN-199201

AbbVie

Phase 2

39

BAY 2701439

Bayer

Phase 2

—10

AGN-190584

AbbVie

Phase 2

4Show 4 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Presbyopia4 trials

Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia

Withdrawn·AbbVie·Phase 2·NCT05393089

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

Completed·AbbVie·Phase 2·NCT02780115·151 enrolled

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

Completed·AbbVie·Phase 2·NCT02595528·163 enrolled

Show 1 more trial

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

Completed·AbbVie·Phase 2·NCT02197806·65 enrolled

Adverse Events1 trial

A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age

Completed·AbbVie·Phase 3·NCT04837482·43 enrolled

Unspecified1 trial

Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses

Withdrawn·GGordon Schanzlin New Vision·Phase 4·NCT05624320

Details

Drug Info

Related News